{
    "2019-05-09": [
        [
            {
                "time": "2018-04-09",
                "original_text": "Top Trending: Chevron backs out of Anadarko deal, Novartis purchases Takeda Eye, Walmart manager salaries",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Takeda",
                        "Eye",
                        "purchase",
                        "deal"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Takeda",
                        "Eye",
                        "Drug",
                        "Deal"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-11",
                "original_text": "Novartisâ€™s $5.3 Billion Eye Disease Deal Adds Cash for Bigger Bets",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Eye",
                        "Disease",
                        "Deal",
                        "Cash"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-12",
                "original_text": "Codexis Bags Novartis as Software Customer, Stays Course in First Quarter",
                "features": {
                    "keywords": [
                        "Codexis",
                        "Novartis",
                        "Software",
                        "Customer"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-13",
                "original_text": "The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Biotech",
                        "Shopping",
                        "Trial",
                        "Results"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-14",
                "original_text": "Stocks making the biggest moves premarket: Disney, Intel, Etsy, Fox Corp, Costco, Novartis & more",
                "features": {
                    "keywords": [
                        "Disney",
                        "Intel",
                        "Etsy",
                        "Fox",
                        "Corp",
                        "Costco",
                        "Novartis"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "various"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "Novartis buys dry eye drug from Takeda for up to $5.3 billion",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Takeda",
                        "Dry",
                        "Eye",
                        "Drug"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-16",
                "original_text": "Novartis to Buy Takeda Eye Drug Assets in $5.3 Billion Deal",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Takeda",
                        "Eye",
                        "Drug",
                        "Assets"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "Takeda sheds products, 485 jobs in deals worth $5.7B",
                "features": {
                    "keywords": [
                        "Takeda",
                        "Products",
                        "Jobs",
                        "Deals"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-18",
                "original_text": "Takeda to sell eye drug to Novartis in $5.3bn deal",
                "features": {
                    "keywords": [
                        "Takeda",
                        "Novartis",
                        "Eye",
                        "Drug",
                        "Deal"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}